# BPC-157 TB-500 Clinical Evidence: What Human Studies Actually Show

> BPC-157 TB-500 clinical evidence, posted straight: zero controlled trials of the combination, three small BPC-157 human pilots, and human safety data for full-length Thymosin Beta-4 — not the TB-500 fragment. Every datum cited.

The combination row reads zero. The constituent rows are thin and, for TB-500, point at the parent protein rather than the fragment. Here is the human dataset, posted line by line.

## The BPC-157 TB-500 clinical evidence, posted straight

BPC-157 TB-500 clinical evidence, read off the published record, divides into three rows — and the most important one is empty. There are no controlled clinical trials of the BPC-157 + TB-500 combination for any indication, and no peer-reviewed combination preclinical study defining a synergy ratio, dose, or endpoint [8]. The "Wolverine" pairing is prominent in marketing and athlete forums; it is absent from the trial registries.

The constituent rows carry the only human exposure data. BPC-157 has three small pilot studies — a two-person intravenous safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot. A 2025 narrative review states that only those three pilot human BPC-157 studies exist and that rigorous large-scale trials are lacking, recommending BPC-157 be treated as investigational [10]. "TB-500" human data, meanwhile, are not for the 7-mer at all: they are for full-length Thymosin Beta-4 [5][6].

The practical reading is direct. Anything presented as proven "Wolverine" clinical efficacy outruns the evidence. The constituent findings are largely preclinical; the combination is untested in humans.

## The human Thymosin Beta-4 dataset — parent protein, not the fragment

Two Phase 1 trials anchor the human safety record for the TB-500 leg — and both used full-length Thymosin Beta-4, not the `Ac-LKKTETQ` fragment that is sold as TB-500. In a randomized, placebo-controlled Phase 1 study, synthetic full-length Thymosin Beta-4 given intravenously to 40 healthy volunteers (`42-1260 mg`, single then daily for 14 days) was well tolerated with no dose-limiting toxicities or serious adverse events and dose-proportional pharmacokinetics [5].

A 2021 first-in-human, randomized, double-blind, placebo-controlled Phase 1 study of intravenous recombinant human Thymosin Beta-4 (NL005) in 84 healthy volunteers (single-ascending-dose `0.05-25.0 microg/kg`; multiple-ascending-dose `0.5-5.0 microg/kg/day x10 days`) reported no dose-limiting toxicities, no serious adverse events, only mild-to-moderate adverse events, and dose-proportional pharmacokinetics with no accumulation [6].

Both are genuine human safety datasets. Neither tests the TB-500 heptapeptide, neither tests the route used in the research community for the blend, and neither tests the combination with BPC-157. The conflation between "TB-500" and full-length Thymosin Beta-4 is the single most repeated error in blend marketing, and it sits on the TB-500 leg of every "Wolverine" claim.

## Wolverine injection: what the route evidence actually covers

Searches for a "Wolverine injection" reach for an injectable combination protocol that the literature does not supply. The predominant research-community routes for the blend are subcutaneous and intramuscular, but those routes appear in community practice, not in controlled human efficacy trials. The underlying rodent efficacy studies for both peptides used intraperitoneal administration [1][3]. The only human injection data are intravenous and single-agent: the BPC-157 IV safety pilot, and the IV full-length Thymosin Beta-4 Phase 1 studies [5][6].

No human study has administered the BPC-157 + TB-500 combination by any route. There is no validated injection schedule, ratio, or dose for the blend. This site does not provide administration instructions; it documents which routes the published studies actually used.

## What recent reviews conclude

The 2024-2026 review literature is consistent. A 2025 HSS Journal systematic review found BPC-157 "shows promise" for musculoskeletal recovery but only from level IV-V evidence, with "no clinical safety data" and no combination or TB-500 data [8]. A 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides described animal-model promise but scarce human safety data and no regulatory approval for unapproved peptides including BPC-157 and TB-500 [9].

A 2025 narrative review titled "Regeneration or Risk?" reached the same place: only three pilot human BPC-157 studies, rigorous large-scale trials lacking, BPC-157 to be treated as investigational [10]. Three independent reviews, one conclusion — the constituent evidence is preclinical-dominant and the combination is untested. The directional reading on this terminal is unchanged: confirmed at the constituent level, a gap at the blend level.

## Frequently asked: clinical-evidence questions

### Are there human clinical trials on the BPC-157 + TB-500 combination?
No. There are zero controlled clinical trials of the BPC-157 + TB-500 combination for any indication, and no peer-reviewed combination preclinical study defining a synergy ratio, dose, or endpoint [8]. Human data exist only for the individual constituents, and the "TB-500" human data are for full-length Thymosin Beta-4, not the fragment [5][6].

### Is the 'Wolverine' synergy claim actually proven?
No. The synergy claim is a theoretical extrapolation from each peptide's separately characterized — and largely non-overlapping — mechanism [1][3]. No controlled combination study has defined a synergistic dose, ratio, or endpoint, and a 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [8].

### Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No such study exists. No peer-reviewed publication defines a combination dose, ratio, or endpoint for the two peptides given together [8]. The mechanisms are complementary on paper — BPC-157 angiogenic and cytoprotective, TB-500 cytoskeletal and pro-migratory — but complementary mechanisms are a hypothesis, not a demonstrated greater-than-additive effect [1][3].

### What do doctors and reviews say about the BPC-157 + TB-500 blend?
Peer-reviewed reviews treat the constituents as investigational. A 2025 HSS Journal review and a 2025 narrative review both note only three small human BPC-157 pilots and a lack of large trials [8][10], and a 2026 Sports Medicine review notes scarce human safety data and no regulatory approval for these unapproved peptides [9]. None endorses the blend as a validated therapy.

---

A two-position evidence board for the BPC-157 TB-500 blend — each constituent finding posted up where the studies confirm it and down where the combination row stays empty, the FDA 503A and WADA status read off first, and nothing here listed, priced, or for sale.